Back to Search Results
Image Place holder

Karen Fields, MD

 
Specialty: Medical Oncology
Sub Specialty: Medical Oncology, Hematology
Program: Breast Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Breast Cancer, Ductal Carcinoma In Situ, Inflammatory Breast Cancer, Invasive Ductal Carcinoma, Triple Negative Breast Cancer

Dr. Karen Fields is a medical oncologist specializing in breast cancer at Moffitt Cancer Center. Dr. Fields is not currently seeing new patients.  Dr. Fields is leading Moffitt’s efforts to improve the quality of care for cancer patients by implementing clinical pathways, quality assurance programs and clinical trials at other centers throughout Florida and the region. She was a founding member of the Blood and Marrow Transplant (BMT) Program at Moffitt and has served in several leadership positions at Moffitt including Chief of Medicine Service, Medical Director of Information Technology and Medical Director of Affiliate Relations. Dr. Fields returned to Moffitt in 2011 following time spent as the Vice President of Global Academic Programs at the M.D. Anderson Cancer Center and the President and CEO of Cancer Therapy and Research Center in San Antonio. Dr. Fields’ early research focused on the role of high dose therapy for the treatment of breast cancer and other cancers.  In the laboratory, she co-developed and validated a method for the detection of breast cancer cells in the blood, bone marrow and lymph nodes.  Additionally, her research efforts have also included studies to understand the psychological and cognitive effects of therapy with interventions aimed at improving the quality of life for patients with breast cancer and other malignancies.  Dr. Fields has published more than 80 articles and book chapters in prestigious journals.  Dr. Fields has received many honors throughout her career and is consistently named one of the Best Doctors in America and one of America’s Top Doctors for Cancer.  


Education & Training

Fellowship:

  • University of Cincinnati - Hematology/Medical Oncology
  • University of Florida Health Science Center - Hematology/Medical Oncology

Residency:

  • The Jewish Hospital of Cincinnati - Internal Medicine

Medical School:

  • Ohio State University - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Bazan JA, Carr Reese P, Esber A, Lahey S, Ervin M, Davis JA, Fields K, Turner AN. High prevalence of rectal gonorrhea and Chlamydia infection in women attending a sexually transmitted disease clinic. J Womens Health (Larchmt). 2015 Mar.24(3):182-189. Pubmedid: 25692800. Pmcid: PMC4363910.
  • Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res. 2011 Dec.17(24):7743-7753. Pubmedid: 22028494. Pmcid: PMC4521635.
  • Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008 Mar.41(6):537-545. Pubmedid: 18084340.
  • Jacobs S, Small B, Booth-Jones M, Jacobsen P, Fields K. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007 Oct.110(7):1560-1567. Pubmedid: 17685391.
  • Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, Fields K, Goldstein S. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May.37(9):851-856. Pubmedid: 16532016.
  • Widows M, Jacobsen P, Booth-Jones M, Fields K. Predictors of posttraumatic growth following bone marrow transplantation for cancer. Health Psychol. 2005 May.24(3):266-273. Pubmedid: 15898862.
  • Xu Q, Brabham J, Zhang S, Munster P, Fields K, Zhao R, Yu H. Chinese herbal formula, Bing De Ling, enhances antitumor effects and ameliorates weight loss induced by 5-fluorouracil in the mouse CT26 tumor model. DNA Cell Biol. 2005 Jul.24(7):470-475. Pubmedid: 16008516.
  • Wilson R, Jacobsen P, Fields K. Pilot study of a home-based aerobic exercise program for sedentary cancer survivors treated with hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Apr.35(7):721-727. Pubmedid: 15696182.
  • Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Elfenbein G, Horowitz MM, Antman KH. Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. Bone Marrow Transplant. 2003 Jul.32(2):151-155. Pubmedid: 12838279.
  • Fields KK. High-dose chemotherapy: changes in approaches and applications. Cancer Control. 2003 Jan.10(1):7. Pubmedid: 12598851.
  • Sadler I, Jacobsen P, Booth-Jones M, Belanger H, Weitzner M, Fields K. Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manag. 2002 May.23(5):406-416. Pubmedid: 12007758.
  • Kutza J, Fields K, Grimm TA, Clouse KA. Inhibition of HIV replication and macrophage colony-stimulating factor production in human macrophages by antiretroviral agents. AIDS Res Ther. 2002 Jun.18(9):619-625. Pubmedid: 12079557.
  • Jacobsen PB, Sadler IJ, Booth-Jones M, Soety E, Weitzner MA, Fields KK. Predictors of posttraumatic stress disorder symptomatology following bone marrow transplantation for cancer. J Consult Clin Psychol. 2002 Feb.70(1):235-240. Pubmedid: 11860050.
  • Fields K, Crump M, Bence-Bruckler I, Bernstein S, Williams S, Frankel S, Miller A, Demetri G, Nabholtz J, Cruickshank S, Lill M. Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2000 Nov.26(10):1083-1088. Pubmedid: 11108307.
  • Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett-Tate C, Adams J, Kuderer N, Lyman G. The uncertainty principle and industry-sponsored research. Lancet. 2000 Aug.356(9230):635-638. Pubmedid: 10968436.
  • Bashey A, Corringham S, Gilpin E, Fields K, Smilee R, DeFrancisco C, Santos-Ada O, Holman P, Carrier E, Ho A, Lane T, Ball E, Janssen W, Law P. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Cytotherapy. 2000.2(3):195-200. Pubmedid: 12042042.
  • Rowlings P, Williams S, Antman K, Fields K, Fay J, Reed E, Pelz C, Klein J, Sobocinski K, et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. Jama. 1999 Oct.282(14):1335-1343. Pubmedid: 10527180.
  • Andrykowski M, Cordova M, Hann D, Jacobsen P, Fields K, Phillips G. Patients' psychosocial concerns following stem cell transplantation. Bone Marrow Transplant. 1999 Nov.24(10):1121-1129. Pubmedid: 10578162.
  • Hann DM, Garovoy N, Finkelstein B, Jacobsen PB, Azzarello LM, Fields KK. Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: a longitudinal comparative study. J Pain Symptom Manag. 1999 May.17(5):311-319. Pubmedid: 10355210.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999.5:3734s-3734s.
  • Djulbegovic B, Hozo I, Fields K, Sullivan D. High-Dose Chemotherapy in the Adjuvant Treatment of Breast Cancer: Benefit/Risk Analysis. Cancer Control. 1998 Oct.5(5):394-405. Pubmedid: 10761089.
  • Fields KK. High-Dose Therapy and Stem Cell Transplantation. Cancer Control. 1998 Oct.5(5):375-376. Pubmedid: 10761087.
  • Hann D, Jacobsen P, Azzarello L, Martin S, Curran S, Fields K. Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res. 1998 May.7(4):301-310. Pubmedid: 9610214.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Goldstein S, Heimenz J, Saez R, Sullivan D, Partyka J, Kronish L. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer. Semin Oncol. 1998 Apr.25(2 Suppl 4):1-6. Pubmedid: 9578055.
  • Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997 Oct.20(8):653-656. Pubmedid: 9383228.
  • Agaliotis D, Ballester O, Mattox T, Hiemenz J, Fields K, Zorsky P, Goldstein S, Perkins J, Rosen R, Elfenbein G. Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation. Am J Med Sci. 1997 Nov.314(5):292-298. Pubmedid: 9365330.
  • Antman K, Rowlings P, Vaughan W, Pelz C, Fay J, Fields K, Freytes C, Gale R, Hillner B, Holland H, Kennedy M, Klein J, Lazarus H, McCarthy P, Saez R, Spitzer G, Stadtmauer E, Williams S, Wolff S, Sobocinski K, Armitage J, Horowitz M. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997 May.15(5):1870-1879. Pubmedid: 9164197.
  • Ballester O, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A, Kronish L, Sullivan P, Elfenbein G. Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma. Brit J Haematol. 1997 Mar.96(4):746-748. Pubmedid: 9074417.
  • Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer. 1997 Jan.5(1):44-52. Pubmedid: 9010989 .
  • Hann DM, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM, Fields KK. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer. 1997 Jan.5(1):44-52. Pubmedid: 9010989.
  • Hann D, Jacobsen P, Martin S, Kronish L, Azzarello L, Fields K. Quality of life following bone marrow transplantation for breast cancer: a comparative study. Bone Marrow Transplant. 1997 Feb.19(3):257-264. Pubmedid: 9028556.
  • Moscinski L, Trudeau W, Fields K, Elfenbein G. High-sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19. Diagn Mol Pathol. 1996 Sep.5(3):173-180. Pubmedid: 8866230.
  • Fields K, Perkins J, Partyka J, Elfenbein G. High-dose therapy for the treatment of breast cancer: evaluation of effect of regimen on outcome. Bone Marrow Transplant. 1996 Sep.18 Suppl 1:S30-S33. Pubmedid: 8899167.
  • Perkins J, Elfenbein G, Fields K. Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Semin Oncol. 1996 Jun.23(3 Suppl 6):42-46. Pubmedid: 8677448.
  • Fields K, Elfenbein G, Trudeau W, Perkins J, Janssen W, Moscinski L. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol. 1996 Jun.14(6):1868-1876. Pubmedid: 8656255.
  • Ballester O, Agaliotis D, Hiemenz J, Janssen W, Fields K, Zorsky P, Goldstein S, Perkins J, Elfenbein G. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery. Bone Marrow Transplant. 1996 Jul.18(1):9-14. Pubmedid: 8831989.
  • Fields K, Partyka J, Perkins J, Elfenbein G. Optimization of high dose therapy for the treatment of patients with metastatic breast cancer. J Oncol Pharm Practice. 1996.2:11-17.
  • Perkins J, Fields K, Elfenbein G. Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. Semin Oncol. 1995 Jun.22(3 Suppl 7):5-8. Pubmedid: 7610398.
  • Fields K, Elfenbein G, Lazarus H, Cooper B, Perkins J, Creger R, Ballester O, Hiemenz J, Janssen W, Zorsky P. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol. 1995 Feb.13(2):323-332. Pubmedid: 7844593.
  • Fields K, Elfenbein G, Perkins J, Perkins J, Moscinski L. High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Ann Ny Acad Sci. 1995 Dec.770:288-304. Pubmedid: 8597367.
  • Janssen WE, Hiemenz JW, Fields KK, Zorsky PE, Ballester OF, Goldstein SC, Elfenbein GJ. Blood and Bone Marrow Hematopoietic Stem Cells for Transplantation: A Comparative Review. Cancer Control. 1994 May.1(3):225-230. Pubmedid: 10886972.
  • Fields KK, Agaliotis DP, Janssen WE, Perkins JB, Ballester OF, Hiemenz JW, Zorsky PE, Elfenbein GJ. High-dose Chemotherapy and the Treatment of Metastatic Breast Cancer: Selecting the Regimen and the Source of Stem Cells. Cancer Control. 1994 May.1(3):213-218. Pubmedid: 10886970.
  • Greene JN, Sandin RL, Fields KK, Moscinski LC, Beatty A, Pow-Sang J, Elfenbein GJ. Hemorrhagic Cystitis in Bone Marrow Transplant Patients: Is It an Infection or Chemotherapy Toxicity?. Cancer Control. 1994 Jul.1(4):411-415. Pubmedid: 10886995.
  • Horton J, Fields K. Progress in management of stage III and inflammatory breast cancer. Intern Med. 1994.2:73-77.
  • Fields K, Zorsky P, Hiemenz J, Kronish L, Elfenbein G. Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. J Clin Oncol. 1994.12(3):544-552.
  • Fields K, Agaliotis D, Janssen W, Perkins J, Ballester O, Hiemenz J, Zorsky P, Elfenbein G. High-dose chemotherapy and the treatment of metastatic breast cancer: selecting the regimen and the source of stem cells. Cancer Control. 1994.1:213-218.
  • Janssen W, Hiemenz J, Fields K, Zorsky P, Ballester O, Goldstein S, Elfenbein G. Blood and bone marrow hematopoietic stem cells for transplantation. Cancer Control. 1994.1(3):225-230.
  • Greene J, Sandin R, Fields K, Moscinski L, Beatty A, Pow-Sang J, Elfenbein G. Hemorrhagic cystitis in bone marrow transplant patients: is it an infection or chemotherapy toxicity?. Cancer Control. 1994.1(4):411-415.
  • Janssen WE, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz JH, Zorsky PE, Fields KK, Ballester O, Perkins J. Mobilization of peripheral blood stem cells: comparing cyclophosphamide and growth factor based regimens. Prog Clin Biol Res. 1994.389:429-439. Pubmedid: 7700915.
  • Balducci L, Benson K, Lyman G, Sanderson R, Fields K, Ballester O, Elfenbein G. Cost-effectiveness of leukocyte depletion filters in adult acute myelogenous leukemia. Transfusion. 1993.33(8):665-670.
  • Fields K, Perkins J, Hiemenz J, Zorsky P, Janssen W, Kronish L, Machak M, Elfenbein G. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. Surg Oncol. 1993.2:87-95.
  • Benson K, Fields K, Hiemenz J, Zorsky P, Ballester O, Perkins J, Elfenbein G. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol. 1993.20:102-109.
  • Fields K, Elfenbein G, Perkins J, Hiemenz J, Janssen W, Zorsky P, Ballester O, Kronish L, Foody M. Two novel high dose treatment regimens for metastatic breast cancer: ifosfamide, carboplatin plus etoposide (ICE) and mitoxantrone plus thiotepa (MITT): outcomes and toxicities. Semin Oncol. 1993.20:59-66.
  • Fields K, Elfenbein G, Hiemenz J, Zorsky P, Pach M. High-dose thiotepa and mitoxantrone with autologous stem cell reinfusion for refractory malignancies: a phase I-II study. Clin Res. 1992.40:421A-421A.
  • Saleh T, Fields K, Elfenbein G, Saleh R, Zorsky P, Janssen W, Perkins J, Piazza J, Kronish L, Machak M, Lyman G. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol. 1992.10:61-74.
  • Fields K. Autologous bone marrow transplantation and melanoma: a focused review of the literature. Ann Plast Surg. 1992.28:70-73.
  • Janssen WE, Benson K, Lee C, Noll L, Smilee R, Fields KK, Zorsky PE, Elfenbein GJ. Salvage and transfusion of autologous red blood cells from bone marrow harvest. Prog Clin Biol Res. 1992.377:337-344. Pubmedid: 1438429.
  • Janssen WE, Lee C, Farmelo MJ, Smilee R, Barth K, Fields KK, Zorsky PE, Elfenbein GJ. Use of CD34+ cell fraction as a measure of hematopoietic stem cells in bone marrow and peripheral blood: comparison with the CFU-GM assay. Prog Clin Biol Res. 1992.377:513-521. Pubmedid: 1279719.
  • Weitzner M, Lehninger F, Sullivan D, Fields K. Borderline personality disorder and bone marrow transplantation: ethical considerations and review. Psychooncology. 8(1):46-54. Pubmedid: 10202782.
  • Fields KK, Elfenbein GJ, Saleh RA, Zorsky PE, Janssen WE, Perkins JB, Saleh TG, Piazza JT, Kronish LE, Machak MC. Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma. Hematol Oncol. 10(1):61-74. Pubmedid: 1563705.
  • Benson K, LeParc G, Vega R, Zorsky P, Fields K, Hiemenz J, Bazzini M, Sandin R, Tourault M, Greene J. 1995;3402.
  • Janssen W, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz J, Zorsky P, Fields K. bMobilization of peripheral blood stem cells (PBSC): Comparing cyclophosphamide and growth factor based regimens. In: Worthington White D, Gee A, Gross S, et al, eds. Advances in Bone Marrow Purging and Processing. New York, NY: Wiley Liss; 1994;429-439.
  • Elfenbein G, Janssen W, Zorsky P, Fields K, Hiemenz J. 1992;201.
  • Fields K, Elfenbein G, Hiemenz J, Zorsky P, Perkins J, Green S, Oelslager P, Kronish L, Holcomb D, Machak M, Sullivan P, Pach M. 1992;714.
  • Agaliotis D, Janssen W, Elfenbein G, Fields K, Hiemenz J, Zorsky P, Perkins J. 1992;516a.
  • Agaliotis D, Fields K, Ballester O, Perkins J, Pach L, Elfenbein G. 1993;1130.
  • Agaliotis D, Hiemenz J, Janssen W, Fields K, Zorsky P, Ballester O, Elfenbein G. 1993;626A.
  • Ballester O, Janssen W, Elfenbein G, Fields K, Hiemenz J, Zorsky P, Kronish L, Beach B, Foody M, Sherman M. 1993;626a.
  • Agaliotis D, Ballester O, Fields K, Hiemenz J, Zorsky P, Goldstein S, Janssen W, Ramirez G, Elfenbein G. 1994;410.
  • Perkins J, Cremers K, Fields K, Janssen W, Ballester O, Goldstein S, Hiemenz J, Zorsky P, Elfenbein G. 1994;782.
  • Fields K, Elfenbein G. 1994;12.
  • Janssen W, Benson K, Lee C, Noll L, Smilee R, Fields K, Zorsky P, Elfenbein G. 1992;337-344.
  • Fields K, Borger D. Disorders of the upper aerodigestive tract associated with high dose therapy and stem cell transplantation. In: Best Practices in Oncology Management: Focus on Swallowing and Communication Disorders. San Diego, CA: Singular Publishing Group; 1998.
  • Perkins J, Fields K, Partyka J, Elfenbein G. Novel high dose regimens for the treatment of breast cancer. In: Dicke K, Keating A, eds. Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. Charlottesville, VA: Carden Jennings; 1997;387-394.
  • Fields K, Elfenbein G, Perkins J, Moscinski L. High dose versus standard dose chemotherapy for the treatment of breast cancer: a review of current concepts. In: Sackstein R, Janssen W, Elfenbein G, et al, eds. Annals of the New York Academy of Sciences. New York, NY: 1995;288-304.
  • Fields K, Elfenbein G. Approaches to high-dose ICE chemotherapy (ifosfamide/carboplatin/etoposide) and autologous stem cell transplantation. Princeton, NJ: Bristol Myers Squibb Company; 1995.
  • Fields K, Partyka J, Elfenbein G, Trudeau W, Kronish L, Perkins J, Moscinski L. Minimal residual disease in the bone marrow of patients with breast cancer undergoing bone marrow transplant: prognostic significance. In: Dicke K, Keating A, eds. Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. Charlottesville, VA: Carden Jennings; 1997;305-312.
  • Elfenbein G, Janssen W, Perkins J, Partyka J, Fields K. Mathematical modeling of human meatopoiesis: lessons learned from the bedside following autologous peripheral blood stem cell transplants. In: Dicke K, Keating A, eds. Autologous Blood and Marrow Transplantation, Proceedings of the 8th International Symposium. Charlottesville, VA: Carden Jennings; 1997;443-466.
  • Fields K, Perkins J, Goldstein S, Elfenbein G, Saez R, Sullivan D, Partyka J, Kronish L. High dose chemotherapy for the treatment of high risk, early stage breast cancer: analysis of risk factors. In: Untech M, Konecny G, Sittek H, Kessler M, et al, eds. Diagnostik and Therapie Des Mammakarzinoms. Verlag, Munchen. W. Zuckeschwerdt; 1998.
  • Fields K, Elfenbein G, Zorsky P, Hiemenz J, Saleh R, Cooper B, Perkins J, Kronish L, Machak M. 1992;202.
  • Fields K, Elfenbein G, Hiemenz J, Zorsky P, Perkins J, Kronish L, Machak M, Pach M. 1993;97.
  • Hiemenz J, Janssen W, Fields K, Zorsky P, Ballester O, Perkins J, Elfenbein G. 1993;1164.
  • Fields K, Moscinski L, Hebel D, Perkins J, Elfenbein G. 1993;144.
  • Fields K, Perkins J, Hiemenz J, Janssen W, Zorsky P, Ballester O, Elfenbein G. 1993;183.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Hiemenz J, Janssen W, Zorsky P. 1994;95.
  • Elfenbein G, Janssen W, Smilee R, Carter R, Rahn D, Cairo M, Hiemenz J, Fields K, Ballester O, Perkins J, Kronish L. 1994;100.
  • Ballester O, Agaliotis D, Elfenbein G, Janssen W, Fields K, Hiemenz J, Zorsky P, Kronish L, Beach B. 1994;410.
  • Elfenbein G, Janssen W, Perkins J, Hiemenz J, Ballester O, Fields K, Goldstein S, Zorsky P. 1994;115.
  • Zorsky P, Fields K, Elfenbein G, Perkins J, Ballester O, Goldstein S, Janssen W, Hiemenz J, Kronish L, Beach B. 1994;384.
  • Ballester O, Agaliotis D, Moscinski L, Fields K, Hiemenz J, Zorsky P, Goldstein S, Saba H, Spiers A. 1994;209.
  • Agaliotis D, Ballester O, Elfenbein G, Janssen W, Fields K, Goldstein S, Hiemenz J, Zorsky P, Perkins J, Kronish L, Beach B. 1994;24.
  • Ballester O, Agaliotis D, Janssen W, Fields K, Hiemenz J, Zorsky P, Goldstein S, Elfenbein G. 1994;782.
  • Elfenbein G, Fields K, Perkins J, Ballester O, Goldstein S, Hiemenz J, Zorsky P. 1994;382.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Hiemenz J, Zorsky P. 1994;779.
  • Janssen W, Hiemenz J, Fields K, Zorsky P, Ballester O, Goldstein S, Smilee R, Kronish L, Elfenbein G. 1994;765.
  • Elfenbein G, Perkins J, Fields K, Ballester O, Goldstein S, Hiemenz J, Janssen W, Zorsky P. 1994;585a.
  • Perkins J, Fields K, Elfenbein G, Ballester O, Goldstein S, Hiemenz J, Zorsky P. 1994;710a.
  • Janssen W, Perkins J, Hiemenz J, Fields K, Zorsky P, Ballester O, Goldstein S, Smilee R, Kronish L, Elfenbein G. 1994;179a.
  • Zorsky P, Janssen W, Lee C, Smilee R, Farmelo M, Barth K, Fields K, Elfenbein G. 1992;513-521.
  • Fields K, Perkins J. Hochdosischemptherapie mit autologer stammzelltransplantation zur behandlung des metastasierten mammakarainoms. In: Untch M, Konecny G, Sittek H, Kepler M, et al, eds. Diagnostil und therapie des mammakarzinoms state of the art. Munchen. W. Zuckschwedt Verlag; 2000;347-359.
  • Fields K, Perkins J, Elfenbein G, Goldstein S, Sullivan D, Pertyka J, Trudeau W. Evaluation of prognostic factors for patients with breast cancer undergoing high-dose chemotherapy and autologous stem cell transplant: a single institution experience. In: Dicke K, Keating A, eds. Autologous blood and marrow transplantation, proceedings of the 9th international symposium. Charlottesville, VA: Carden Jennings; 1999;341-352.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Hiemenz J, Zorsky P. Event-free survival in breast cancer patients treated with high-dose ifosfamide, carboplatin and etoposide and autologous stem cell rescue: analysis of risk factors. In: Einhorn J, Nord C, Norrby S, et al, eds. Recent advances in chemotherapy, proceedings of the 18th interanational congress of chemotherapy. Washington D.C.. 1994;974-975.
  • Janssen W, Elfenbein G, Fields K, Hiemenz J, Zorsky P, Ballester O, Goldstein S, Smilee R, Kronish L, Beach B, Leparc G. Comparison of cell collections and rates of post-transplant granulocyte recovery when G-CSF and GM-CSF are used as mobilizers of peripheral blood stem cells for autotransplantation. In: Dicke K, Keating A, eds. Autologous Bone Marrow Transplantation, Proceedings of the 7th International Symposium. Arlington, TX: 1995;527-539.
  • Fields K, Vesole D, Rowlings P, Horowitz M, Elfenbein G. Bone marrow transplantation in the older patient. In: Balducci L, Lyman G, Erschler W, et al, eds. Geriatric Oncology. The Netherlands. Harwood Academic Publishers; 1998;471-480.
  • Fields K, Goldstein S, Clark R, Sullivan D. Breast Cancer. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology: Evidence Based Management. New York, NY: Churchill Livingstone Inc.; 1997;253-265.

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments